Toyobo Co. Ltd. – FDA 483, Jul 30, 2019
Toyobo Co. Ltd. in Otsu, Shiga, Japan, a sterile drug manufacturer, was cited for significant deficiencies during an FDA inspection. Observations included a lack of written procedures for production and process controls, inadequate quality control unit procedures for CAPA effectiveness, insufficient controls over computer systems for analytical data, and inadequate validation of aseptic processes to prevent microbial contamination. These issues indicate a broad failure to ensure drug product quality, purity, and sterility.
ID · fbacef8e-d077-4541-b097-cc06e346bad0
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.